The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

NCT02269267 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Chronic

Interventions

DRUG: Imatinib (Stopping their TKI)
DRUG: Dasatinib (Stopping their TKI)
DRUG: Nilotinib (Stopping their TKI)
DRUG: Bosutinib (Stopping their TKI)

Sponsor

Medical College of Wisconsin

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]